Testosterone for Women: What Is It Actually Good For?
By Ilya Rabkin, MD, MBA ·
Quick Takeaway
- The strongest evidence for testosterone in women is for persistent, distressing low sexual desire, particularly after menopause.
- Mood and energy may improve in some women, but the evidence is much less settled. Brain fog and sleep are even less certain.
- Testosterone clearly affects muscle biology, but normal female replacement doses have not reliably produced meaningful gains in muscle or strength. Bone data are interesting but early.
- A new 2026 observational study raised a cardiovascular safety signal. It deserves attention, but it does not prove that testosterone caused the cardiovascular events.
- Dose and formulation matter. The goal is to use an appropriate dose while keeping testosterone within the physiologic female range.
- Before starting treatment, I think the most useful question is simple: What are we trying to improve, and how will we know if it worked?
“My Testosterone Is Low. Should I Replace It?”
I’m hearing this question more often.
Testosterone prescribing to women in the United States rose about 2.6-fold from 2016 through 2025, with use concentrated particularly in women ages 45 to 64.1 At the same time, testosterone is being discussed for a much wider range of symptoms: libido, fatigue, mood, brain fog, muscle, sleep, weight, and general “optimization.”
Those claims don’t all have the same evidence behind them.
A low testosterone result by itself also doesn’t diagnose a testosterone deficiency syndrome in women. Current guidance does not define a blood level below which an otherwise healthy woman can simply be labeled testosterone deficient and automatically treated.2, 3, 4, 5
That’s why I usually start somewhere else: what symptom are we actually trying to improve?
Where the Evidence Is Strongest: Sexual Desire
The best-supported use of testosterone in women is hypoactive sexual desire disorder, or HSDD. In practical terms, this means persistent low sexual desire that is distressing to the woman after other contributors have been considered.
Sexual desire is complicated. Estrogen status, vaginal dryness or pain, sleep, depression, medications, relationship factors, stress, body image, and chronic illness can all affect it. A testosterone prescription shouldn’t replace that evaluation.
When distressing low desire persists, though, testosterone has meaningful randomized-trial evidence behind it.
A 2019 systematic review pooled 36 randomized trials involving 8,480 women. Testosterone improved sexual desire along with several related measures of sexual function and sexual distress in postmenopausal women.3 Current menopause and sexual-medicine guidance continues to recognize postmenopausal HSDD as the clearest evidence-based indication for a trial of physiologic testosterone.2, 3, 4, 5
The average benefit is moderate, not dramatic. But this is one area where we can reasonably tell a patient that the treatment has been tested against placebo and shown to help.
Energy, Mood, Brain Fog, and Sleep
Beyond sexual desire, the evidence gets much less certain. This is also where I hear some of the more interesting patient experiences.
Women sometimes describe better energy, motivation, mood, concentration, and sleep after starting testosterone. Published studies report some of the same changes. The harder question is how confident we can be that testosterone itself caused them.
Energy and mood
One study often cited in this discussion looked back at the records of 510 peri- and postmenopausal women treated at a single specialist menopause clinic. All were already using estrogen-based hormone therapy and then added transdermal testosterone. Four months later, 43% of women who had reported fatigue or low energy said it had improved. Mood symptoms also improved in a substantial proportion of women.6
Those findings interest me because they resemble what some women report clinically.
But this was a retrospective study without a placebo group. Everyone knew they were receiving treatment, and the women were being managed in a specialty menopause clinic. The improvement could reflect testosterone, other aspects of treatment, expectations, or some combination of those factors.
Older randomized evidence has not established testosterone as a reliable treatment for depression or general well-being.3, 5 So I wouldn’t prescribe it as an antidepressant or promise that it will fix fatigue.
I also don’t think the observational findings should simply be discarded. There may be something there. We need better trials to know how much of the effect is truly attributable to testosterone and which women are most likely to experience it.
Brain fog
Brain fog is another good example of the difference between what patients report and what clinical trials have measured.
Women describe trouble finding words, losing their train of thought, poor concentration, or simply feeling mentally slower than they used to. The 510-woman study reported improvement in memory and concentration after testosterone was added.6
A 2026 systematic review looked specifically at testosterone and cognition during and after menopause. Only five studies met the criteria. Three randomized trials involving 244 postmenopausal women could be combined, and testosterone did not significantly improve formal measures of executive function, verbal memory, or visuospatial memory.7
That sounds fairly clear until you look at the limitations.
The evidence was rated very low certainty, the studies were small, and none specifically studied subjective brain fog during perimenopause.7 That may be different from asking someone to perform better on a formal memory test.
So the current evidence isn’t strong enough for me to tell a woman that testosterone is proven to treat brain fog. I also wouldn’t tell someone who feels mentally sharper on treatment that her experience is meaningless. This is an area where the clinical anecdotes have moved ahead of the research.
Sleep
Sleep has even less direct evidence.
Some women report sleeping better on testosterone, but it’s difficult to know whether testosterone is directly changing sleep or whether sleep improves because mood, sexual well-being, exercise, or other menopausal symptoms improve.
At this point, I wouldn’t use testosterone specifically as a sleep treatment.
We have stronger evidence for addressing the reason someone isn’t sleeping, including treating vasomotor symptoms when they are waking her up, selected use of estrogen or micronized progesterone, and cognitive behavioral therapy when persistent insomnia is the primary problem.2
Muscle: The Biology Is Convincing, the Clinical Benefit Less Clear
Testosterone is anabolic, so the muscle question makes sense.
A small mechanistic study found that testosterone increased muscle protein synthesis in postmenopausal women.8 There is a plausible biological reason to think testosterone could affect muscle.
What has been harder to demonstrate is a meaningful improvement in muscle mass or function at the doses normally used for female hormone therapy. The larger randomized evidence has not shown consistent improvements in body composition or musculoskeletal outcomes at physiologic female doses.3, 5
One dose-ranging trial helps explain some of that disconnect. Women were assigned to different testosterone dose groups, and lean mass and measures of muscle performance improved as testosterone exposure increased. The more meaningful changes occurred mainly in the highest-dose group, where testosterone levels were well above the usual female physiologic range.9
In other words, testosterone certainly has the biological ability to affect muscle. That doesn’t prove that standard female replacement doses reliably produce a clinically meaningful muscle-building effect.
I wouldn’t use physiologic testosterone primarily as a muscle-building treatment. Resistance training, adequate protein, and enough total nutrition have much stronger evidence.
There may eventually turn out to be a subgroup of women who gets a meaningful musculoskeletal benefit from physiologic treatment. We don’t have enough evidence yet to define that group.
Bone Density: Interesting, but Early
Testosterone is not an established treatment for osteoporosis. Earlier studies have been small, and most have also involved estrogen, which makes the contribution of testosterone difficult to separate.5
A study presented at The Menopause Society’s 2026 meeting adds an interesting signal.
Researchers looked at 51 postmenopausal women who had been treated with estrogen alone and later with estrogen plus testosterone. Lumbar-spine T-scores improved after testosterone was added, while hip and femoral-neck measurements did not change significantly.10
I find that interesting, but it is very early evidence.
This was a small retrospective study presented as a conference abstract, not a large randomized fracture-prevention trial. It also cannot tell us whether testosterone protects bone independently of estrogen.
For now, this is research I’ll continue to watch rather than a reason to prescribe testosterone for osteoporosis.
Dose and Formulation Matter
“Testosterone therapy” can describe very different treatments.
Most of the guideline evidence is based on transdermal testosterone given at doses intended to keep levels within the normal premenopausal female range.2, 3, 4, 5 There is still no FDA-approved testosterone product specifically formulated for women in the United States, which makes real-world prescribing less straightforward.1
Gels and creams are commonly used because the dose can be adjusted and treatment can be stopped quickly. The tradeoffs are daily application, measuring very small doses when a male product is being adapted, and the possibility of transferring medication through skin contact.
Pellets are appealing to some women because they are convenient and don’t require daily treatment. Once implanted, though, the dose is much harder to change or reverse. Pellets and some injection regimens can also produce testosterone concentrations above the normal female range.
Injections can be convenient, but depending on the dose and interval they may create larger peaks and troughs.
Oral testosterone is generally avoided because randomized studies have shown unfavorable effects on lipid profiles.3
Major professional guidelines are also cautious about compounded testosterone because dosing consistency, efficacy, and safety are less standardized than with regulated commercial products.2, 4 In actual practice, the absence of a female-specific FDA-approved product is one reason compounded preparations and modified male formulations remain common.
At physiologic dosing, acne and increased facial or body hair are among the more common androgenic effects.3, 5 Excessive exposure raises more concern for unwanted androgenic effects, which is another reason monitoring matters.
Whatever formulation is chosen, I care much more about keeping the dose physiologic and determining whether the patient is actually improving than about pushing a testosterone number higher.
What About the Recent Cardiovascular Headlines?
The most important new safety question is cardiovascular risk.
At The Menopause Society’s 2026 meeting, researchers presented an electronic-health-record study of postmenopausal women age 45 and older. Women with prior cardiovascular disease were excluded.
After statistical matching, 3,164 testosterone users were compared with 3,164 women who had not received testosterone. The women were followed for an average of roughly 2.6 years. Cardiovascular diagnoses occurred in 3.8% of testosterone users compared with 0.5% of controls.11
That is a large enough signal that I don’t think it should be brushed aside.
It is equally important to understand what the study can and cannot tell us.
This was an observational study. Researchers looked backward at medical records rather than randomly assigning women to testosterone or placebo.
They did a good job trying to make the groups similar by matching for a number of cardiovascular risk factors. That makes the comparison more useful, but it cannot account for every difference between women who received testosterone and women who did not.
The study also didn’t give us enough information to determine whether risk differed according to testosterone dose, route, formulation, or achieved blood level. Those differences could matter considerably.
Women with established cardiovascular disease were excluded, so the study also cannot answer what testosterone does in women who already have coronary disease or are otherwise at particularly high cardiovascular risk.
And although the women were age 45 and older, the study did not show that younger women had a different cardiovascular response from older women.
That means I would be careful about borrowing the estrogen “timing hypothesis” and applying it to testosterone. We simply don’t have evidence that starting testosterone younger eliminates cardiovascular risk.
The researchers themselves described the findings as hypothesis-generating and called for prospective confirmation.11
Before this study, randomized trials using physiologic testosterone doses had generally been reassuring over the short term. But those trials often excluded women at higher cardiometabolic risk, and long-term safety was never firmly established.5
So I see this study as a meaningful safety signal, not a final answer.
It doesn’t prove that appropriately prescribed testosterone causes cardiovascular disease. It does make the need for better long-term data more important, especially as testosterone use in women continues to grow.
Before Starting: What Are We Trying to Fix?
Before prescribing testosterone, I find it useful to define what success would actually look like.
If the problem is sexual desire, are desire and the associated distress improving?
If the hope is better energy, what does that mean in everyday life? Getting through the afternoon without crashing? Exercising again? Feeling more motivated?
If the complaint is brain fog, are concentration, word-finding, or mental stamina noticeably better?
That conversation often uncovers other explanations too.
Low estrogen, poor sleep, vaginal pain, thyroid disease, iron deficiency, depression, anxiety, medication effects, inadequate nutrition, relationship stress, and other medical issues can overlap with symptoms that get attributed to “low testosterone.”
A testosterone level is useful before treatment and for monitoring, but the number itself is not the diagnosis or the goal.2, 4
If we start treatment and the symptom we were trying to treat doesn’t meaningfully improve after an adequate trial, I would question the value of continuing simply because the testosterone level increased.
Where I Land
Testosterone has a legitimate role in women’s health, but the strength of the evidence depends heavily on what we’re trying to treat.
For persistent, distressing low sexual desire after menopause, the evidence is fairly strong.
Mood and energy have some interesting signals but not the same level of proof. Brain fog and sleep remain much less certain. Muscle and bone make biological sense and have some early data behind them, but they are not established reasons to prescribe testosterone.
The cardiovascular findings from 2026 add another reason to pay attention to indication, baseline risk, dose, and formulation. They do not prove that appropriately prescribed testosterone causes cardiovascular disease, but the signal is substantial enough that I want to see better prospective data.
My approach is to define the problem first, use a physiologic dose when treatment makes sense, and decide ahead of time what improvement should look like.
If the patient isn’t meaningfully better, a higher testosterone number by itself isn’t much of a treatment goal.
References
- Avivi I, Stuenkel CA, Sampath-Kumar R, Ben-Yehuda O. Accelerating testosterone prescribing for U.S. women: implications for cardiovascular safety. JACC Adv. 2026;5(6 Pt 1):102724. doi:10.1016/j.jacadv.2026.102724. Read source
- Panay N, Fenton A, Hamoda H, et al.; IMS Recommendations Writing Group. International Menopause Society (IMS) recommendations and key messages on women’s midlife health and menopause. Climacteric. 2025;28(6):634-656. doi:10.1080/13697137.2025.2585487. Read source
- Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019;7(10):754-766. doi:10.1016/S2213-8587(19)30189-5. Read source
- Parish SJ, Simon JA, Davis SR, et al. International Society for the Study of Women’s Sexual Health clinical practice guideline for the use of systemic testosterone for hypoactive sexual desire disorder in women. J Sex Med. 2021;18(5):849-867. doi:10.1016/j.jsxm.2020.10.009. Read source
- Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the use of testosterone therapy for women. J Clin Endocrinol Metab. 2019;104(10):4660-4666. doi:10.1210/jc.2019-01603. Read source
- Glynne S, Kamal A, Kamel AM, Reisel D, Newson L. Effect of transdermal testosterone therapy on mood and cognitive symptoms in peri- and postmenopausal women: a pilot study. Arch Womens Ment Health. 2025;28(3):541-550. doi:10.1007/s00737-024-01513-6. Read source
- Faulkner A, Desai R, Keay N, Ellahi SA, Spector A. Testosterone therapy for cognition in menopause: a systematic review and meta-analysis. Reprod Fertil. 2026;7(4):RAF260080. doi:10.1530/RAF-26-0080. Read source
- Smith GI, Yoshino J, Reeds DN, et al. Testosterone and progesterone, but not estradiol, stimulate muscle protein synthesis in postmenopausal women. J Clin Endocrinol Metab. 2014;99(1):256-265. doi:10.1210/jc.2013-2835. Read source
- Huang G, Basaria S, Travison TG, et al. Testosterone dose-response relationships in hysterectomized women with or without oophorectomy: effects on sexual function, body composition, muscle performance and physical function in a randomized trial. Menopause. 2014;21(6):612-623. doi:10.1097/GME.0000000000000093. Read source
- Davis S, Shoupe D, Sriprasert I, Huang J. Effect of combined estrogen and testosterone therapy on bone mineral density in postmenopausal women. Presented at: The Menopause Society 2026 Annual Meeting; October 20-24, 2026; San Diego, CA. Abstract P-24. Conference abstract P-24 · Society summary
- Jiang XD, Amin S. Testosterone therapy and cardiovascular risk in postmenopausal women: a retrospective propensity-matched cohort study. Presented at: The Menopause Society 2026 Annual Meeting; October 20-24, 2026; San Diego, CA. Abstract P-59. Conference abstract P-59 · Society summary
Medical Disclaimer
This article is for educational purposes and does not provide individualized medical advice, diagnosis, or treatment. Decisions about testosterone therapy or other hormone treatment should be individualized based on symptoms, medical history, cardiovascular and cancer risk, laboratory findings, other medications, and a discussion of the potential benefits, uncertainties, and risks.
Editorial Disclosure
This article was written by Ilya Rabkin, MD, MBA, with AI-assisted research organization, reference checking, and editorial support. All clinical interpretations, recommendations, and references were reviewed by Dr. Rabkin before publication.